title: Effects of the systemic beta-adrenoceptor antagonist nebivolol on ocular hemodynamics in glaucoma patients.
abstract: BACKGROUND
  Systemic antihypertensive treatment in glaucoma patients with hypertension carries the potential risk of an additional deterioration in ocular hemodynamics due to the reduction in ocular perfusion pressure. Nebivolol is a beta1-selective adrenoceptor antagonist with known peripheral vasodilatory effects due to NO-releasing properties. The effect of a switch in systemic beta-blocker treatment to nebivolol on retrobulbar hemodynamics in glaucoma patients with arterial hypertension was therefore investigated.
  
  
  METHODS
  Peak systolic (PSV) and end-diastolic (EDV) velocity in the short and long posterior ciliary arteries (SPCA, LPCA), central retinal artery (CRA), and ophthalmic artery (OA) were recorded by color Doppler imaging (CDI) in 23 glaucoma patients with arterial hypertension using their primary systemic beta-blocker medication and four weeks after a switch to nebivolol.
  
  
  RESULTS
  Compared with the first recording under the primary antihypertensive medication, the CDI measurements after four weeks of nebivolol treatment revealed a significant acceleration of the PSV in the SPCA and LPCA and the EDV in the SPCA and CRA. No significant differences in flow velocities were found for the OA. Intraocular pressure and systemic blood pressure remained unchanged.
  
  
  CONCLUSIONS
  Switching blood pressure treatment to nebivolol in glaucoma patients with hypertension leads to accelerated blood flow in the small retrobulbar vessels. A stabilization of ocular perfusion might be of particular importance in this group of co-morbid patients.
authors.affiliation: Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. zeitz@uke.uni-hamburg.de
authors.forename: Oliver
authors.initials: O
authors.lastname: Zeitz
authors.forename: Peter
authors.initials: P
authors.lastname: Galambos
authors.forename: Nataliya
authors.initials: N
authors.lastname: Matthiesen
authors.forename: Lars
authors.initials: L
authors.lastname: Wagenfeld
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Schillinger
authors.forename: Anne
authors.initials: A
authors.lastname: Wiermann
authors.forename: Gisbert
authors.initials: G
authors.lastname: Richard
authors.forename: Maren
authors.initials: M
authors.lastname: Klemm
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001578:Benzopyrans / Q000627:therapeutic use*; D003971:Diastole / Q000187:drug effects; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D013599:Systole / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol